Cyberounds Logo
August 11, 2020 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Hemophagocytic Syndrome in Rheumatic Diseases
CME credit is no longer available for this conference.
Arlene Tan Tieng, M.D., Irene Blanco, M.D., and Peter Barland, M.D.

Drs. Tieng and Blanco are rheumatology fellows, and Dr. Barland is Professor Emeritus of Medicine and Pathology, the Albert Einstein College of Medicine, Bronx, NY.

Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose.


Release Date: 08/10/2009
Termination Date: 08/10/2012

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Define the hemophagocytic syndrome (HPS)
  • List the rheumatic diseases that have been associated with reactive HPS
  • Describe the clinical and lab manifestations of this disorder
  • Discuss the life-saving treatments that should be considered early when autoimmune-associated hemophagocytic syndrome (AAHS) is suspected.

 
The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity